Quarterly results · PPLPHARMA
PIRAMAL PHARMA LIMITED reported revenue of ₹2,617 cr and net profit of ₹5.58 cr in Q2 FY27 (quarter ended 30 Sept 2026). Below is the full quarter-wise results table with revenue, operating profit, margins, tax, EPS and annual history — updated when Yahoo Finance publishes updated financial statements; exchange filings can appear earlier.
| Quarter | Q2 FY27 |
|---|---|
| Quarter ended | 30 Sept 2026 |
| Revenue | ₹2,617 cr |
| Revenue YoY | — |
| Operating profit | ₹116 cr |
| Operating margin | 4.4% |
| Net profit | ₹5.58 cr |
| Net profit YoY | — |
| Net profit QoQ | +108.0% |
| Net margin | 0.2% |
| Basic EPS | ₹0.04 |
| TTM revenue | ₹9,779 cr |
| TTM net profit | -₹209 cr |
| TTM net margin | -2.1% |
PIRAMAL PHARMA LIMITED (PPLPHARMA) has reported its Q2 FY27 results for the quarter ended 2026-09-30. The company posted revenue of ₹2,617 cr and a net profit of ₹5.58 cr, translating into earnings per share of ₹0.04.
Operating profit for the quarter stood at ₹116 cr, an operating margin of 4.4%.
Revenue
₹2,617 cr
— YoY
Net profit
₹5.58 cr
— YoY
Operating profit
₹116 cr
— YoY
EPS
₹0.04
— YoY
| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|---|---|---|---|---|---|---|---|
| Q2 FY272026-09-30 | ₹2,617 cr | ₹116 cr | ₹5.58 cr | 4.4% | 0.2% | ₹0.04 | — | +108.0% |
| Q1 FY272026-06-30 | ₹2,270 cr | -₹28.35 cr | -₹69.39 cr | -1.2% | -3.1% | ₹-0.52 | +15.1% | -686.7% |
| Q4 FY262026-03-31 | ₹2,752 cr | ₹242 cr | -₹8.82 cr | 8.8% | -0.3% | ₹-0.07 | — | +93.5% |
| Q3 FY262025-12-31 | ₹2,140 cr | -₹17.01 cr | -₹136 cr | -0.8% | -6.4% | ₹-1.03 | — | -66.7% |
| Q1 FY262025-06-30 | ₹1,934 cr | -₹90.58 cr | -₹81.7 cr | -4.7% | -4.2% | ₹-0.62 | — | — |
| TTM (last 4 quarters) | ₹9,779 cr | ₹312 cr | -₹209 cr | 3.2% | -2.1% | ₹-1.58 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
| Particulars | Q2 FY272026-09-30 | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q1 FY262025-06-30 |
|---|---|---|---|---|---|
| Revenue / Sales | ₹2,617 cr | ₹2,270 cr | ₹2,752 cr | ₹2,140 cr | ₹1,934 cr |
| Total expenses | ₹2,501 cr | ₹2,298 cr | ₹2,510 cr | ₹2,157 cr | ₹2,024 cr |
| Gross profit | ₹1,711 cr | ₹1,418 cr | ₹1,696 cr | ₹1,354 cr | ₹1,240 cr |
| Operating profit (EBIT) | ₹116 cr | -₹28.35 cr | ₹242 cr | -₹17.01 cr | -₹90.58 cr |
| Operating margin | 4.4% | -1.2% | 8.8% | -0.8% | -4.7% |
| Interest cost | ₹87.63 cr | ₹88.08 cr | ₹82.99 cr | ₹89.24 cr | ₹86.15 cr |
| Profit before tax | ₹81.63 cr | -₹7.46 cr | ₹43 cr | -₹93.86 cr | -₹79.02 cr |
| Tax expense | ₹76.6 cr | ₹61.93 cr | ₹51.83 cr | ₹42.33 cr | ₹2.68 cr |
| Effective tax rate | 93.8% | -830.2% | 120.5% | -45.1% | -3.4% |
| Net profit (PAT) | ₹5.58 cr | -₹69.39 cr | -₹8.82 cr | -₹136 cr | -₹81.7 cr |
| Net profit margin | 0.2% | -3.1% | -0.3% | -6.4% | -4.2% |
| Basic EPS | ₹0.04 | ₹-0.52 | ₹-0.07 | ₹-1.03 | ₹-0.62 |
| Diluted EPS | ₹0.04 | ₹-0.52 | ₹-0.07 | ₹-1.03 | ₹-0.62 |
| Growth | Q2 FY27 | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q1 FY26 |
|---|---|---|---|---|---|
| Revenue YoY | — | +17.4% | — | — | — |
| Revenue QoQ | +15.3% | -17.5% | +28.6% | +10.7% | — |
| Operating profit YoY | — | +68.7% | — | — | — |
| Operating profit QoQ | +507.7% | -111.7% | +1523.5% | +81.2% | — |
| Net profit YoY | — | +15.1% | — | — | — |
| Net profit QoQ | +108.0% | -686.7% | +93.5% | -66.7% | — |
| EPS YoY | — | +16.1% | — | — | — |
| EPS QoQ | +107.7% | -642.9% | +93.2% | -66.1% | — |
Full-year performance for PIRAMAL PHARMA LIMITED, useful for reading each quarter in context.
| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|---|---|---|---|
| Revenue / Sales | ₹8,759 cr | ₹9,061 cr | ₹8,106 cr | ₹7,032 cr |
| Total expenses | ₹8,604 cr | ₹8,382 cr | ₹7,644 cr | ₹7,080 cr |
| Gross profit | ₹5,175 cr | ₹5,489 cr | ₹4,848 cr | ₹4,032 cr |
| Operating profit (EBIT) | ₹155 cr | ₹679 cr | ₹462 cr | -₹47.97 cr |
| Operating margin | 1.8% | 7.5% | 5.7% | -0.7% |
| Interest cost | ₹338 cr | ₹418 cr | ₹447 cr | ₹338 cr |
| Profit before tax | -₹176 cr | ₹415 cr | ₹179 cr | -₹120 cr |
| Tax expense | ₹150 cr | ₹324 cr | ₹161 cr | ₹66.31 cr |
| Effective tax rate | -85.1% | 78.0% | 90.1% | -55.2% |
| Net profit (PAT) | -₹326 cr | ₹91.13 cr | ₹17.82 cr | -₹186 cr |
| Net profit margin | -3.7% | 1.0% | 0.2% | -2.7% |
| Basic EPS | ₹-2.46 | ₹0.69 | ₹0.14 | ₹-1.54 |
| Diluted EPS | ₹-2.46 | ₹0.69 | ₹0.14 | ₹-1.54 |
Topline for Q2 FY27 came in at ₹2,617 cr, and ₹2,270 cr in the preceding Q1 FY27 quarter.
On a sequential basis revenue grew +15.3%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹2,501 cr, or 95.6% of revenue.
Net profit of ₹5.58 cr works out to a net margin of 0.2%.
Below the operating line, PIRAMAL PHARMA LIMITED reported profit before tax of ₹81.63 cr, a tax charge of ₹76.6 cr (effective rate 93.8%), interest cost of ₹87.63 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from -₹69.39 cr in Q1 FY27 to ₹5.58 cr in Q2 FY27, a change of +108.0%.
Across the trailing four quarters PIRAMAL PHARMA LIMITED has generated revenue of ₹9,779 cr and net profit of -₹209 cr, a trailing net margin of -2.1%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹8,759 cr with net profit of -₹326 cr and EPS of ₹-2.46, versus the prior year where revenue declined -3.3% and profit declined -457.7%.
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
No next results date is available in the board-meeting calendar. Statement figures update when Yahoo Finance makes them available; this is not an immediate exchange-filing feed.
Financial figures here are supplied through Yahoo Finance fundamentals and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
No results report published for PPLPHARMA yet — our desk covers each quarter within minutes of the filing.
| Board meeting date | Purpose | Details |
|---|---|---|
| 27 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
Piramal Pharma (PPLPHARMA) last traded at ₹230.60, -2.20 (-0.95%). The in-focus trigger, the levels the tape is defending, and what the numbers mean for traders and long-term holders.
Piramal Pharma (PPLPHARMA) last traded at ₹198.72, +3.55 (+1.82%). The quarterly-results trigger, the levels the tape is defending, and what the numbers mean for traders and long-term holders.
Piramal Pharma (PPLPHARMA) trades at ₹211.35, -1.14 (-0.54%). The in-focus trigger, the levels the tape is defending, and what the numbers mean for traders and long-term holders.
Piramal Pharma (PPLPHARMA) trades at ₹211.35, -1.14 (-0.54%). We read the exchange board, the volume against its own average, and what a shareholder should actually do with this information.
In Q2 FY27 (quarter ended 30 Sept 2026), PIRAMAL PHARMA LIMITED reported revenue of ₹2,617 cr and net profit of ₹5.58 cr. EPS stood at ₹0.04.
PIRAMAL PHARMA LIMITED posted a net profit margin of 0.2% and an operating margin of 4.4% in Q2 FY27. On a trailing twelve-month basis, revenue is ₹9,779 cr and net profit -₹209 cr.
PIRAMAL PHARMA LIMITED net profit changed +108.0% quarter on quarter, from -₹69.39 cr in Q1 FY27 to ₹5.58 cr in Q2 FY27.
PIRAMAL PHARMA LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Results coverage for PPLPHARMA will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the PPLPHARMA stock page.
For FY26, PIRAMAL PHARMA LIMITED reported full-year revenue of ₹8,759 cr and net profit of -₹326 cr, with EPS of ₹-2.46.
PPLPHARMA has held 1 recent board meetings for financial results, the last on 27 Oct 2026.
Results dates: NSE board-meeting calendar. Financial figures: Yahoo Finance fundamentals, not a direct exchange filing feed. Last successful data fetch 30 Oct 2026. Figures can be delayed; results change only when the provider publishes them. For information only, not investment advice.
